REFRACTORY MYCOSIS FUNGOIDES

Clinical trials for REFRACTORY MYCOSIS FUNGOIDES explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY MYCOSIS FUNGOIDES trials appear

Sign up with your email to follow new studies for REFRACTORY MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 3 Completed 1 Terminated 1

Early trial halted for advanced skin cancer combo

Disease control Terminated

This early-phase study tested a combination of two antibody drugs, magrolimab and mogamulizumab, for patients with advanced T-cell skin lymphomas that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and see if adding magrolimab help…

Matched conditions: REFRACTORY MYCOSIS FUNGOIDES

Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

REFRACTORY MYCOSIS FUNGOIDES

Get alerted when new REFRACTORY MYCOSIS FUNGOIDES trials appear

Early trial halted for advanced skin cancer combo